Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1210-1217

  De Boer, Richard ^a   Clemens, Michael ^b   Renczes, Gabor ^c,j   Kotasek, Dusan ^d   Prausova, Jana ^e   Marschner, Norbert ^f   Hedenus, Michael ^g   Doshi, Sameer ^h   Hendricks, Lisa ^h   Österborg, Anders C ⁱ  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Klinikum Mutterhaus de Borromaerinnen GmbH   (Germany)

^c Goodwill Research Ltd   (Hungary)

^d Adelaide Cancer Centre   (Australia)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f Onkologische Schwerpunktpraxis   (Germany)

^g SUNDSVALL HOSPITAL   (Sweden)

^h AMGEN INC   (United States)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j GXP Ltd   (Hungary)

more..

Author keywords

Anaemia; Erythropoiesis; Haemoglobin; Phase 1 clinical trial; Phase 2 clinical trial; Randomised controlled trial

Indexed keywords

AMG 114; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VOMITING;

ANEMIA; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS;

EID: 84655164989     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9725-7     Document Type: Article

References (18)

1. JC Egrie 1986 Characterization and biological effects of recombinant human erythropoietin Immunobiology 172 213 224
2. JC Egrie E Dwyer JK Browne A Hitz MA Lykos 2003 Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin Exp Hematol 31 290 299
3. JC Egrie JK Browne 2001 Development and characterization of novel erythropoiesis stimulating protein (NESP) Br J Cancer 84 Suppl 1 3 10
4. H Ludwig 2009 Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia J Clin Oncol 27 2838 2847
5. J Bohlius 2009 Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 1532 1542
6. ® (darbepoetin alfa) prescribing information, Thousand Oaks, Calif.: Amgen Inc.; 2010.
7. ® (epoetin alfa) prescribing information, Bridgewater, New Jersey: Ortho Biotech Products LP; 2010.
8. European Medicines Agency. Questions and answers on epoetins and the risk of tumour growth and blood clots in the veins, 26 June 2008. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2009/11/ WC500015145.pdf. Accessed 16 Sep 2010.
9. RA Beveridge 2003 Impact of long-acting growth factors on practice dynamics and patient satisfaction Pharmacotherapy 23 101S 109S
10. AC Houts GA Loh BV Fortner JD Kallich 2006 Patient and caregiver time burden associated with anaemia treatment in different patient populations Support Care Cancer 14 1195 1204
11. L Schwartzberg 2003 A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia Clin Ther 25 2781 2796
12. JD Herrington 2005 Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia Am J Health Syst Pharm 62 54 62
13. VA Morrison 2007 Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 weeks chemotherapy regimens in community oncology practices J Manag Care Pharm 13 337 348
14. J Glaspy 2005 Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa Eur J Cancer 41 1140 1149
15. Elliott S, et al. Evaluation of hyperglycosylated erythropoiesis stimulating proteins developed using glycoengineering. Proc Amer Assoc Cancer Res. 2006;47 (Abstract 2176).
16. S Elliott 2004 Control of rHuEPO biological activity: the role of carbohydrate Exp Hematol 32 1146 1155
17. JL Canon 2006 Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia J Natl Cancer Inst 98 273 284
18. J Vansteenkiste 2002 Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 1211 1220